Intervention Review

You have free access to this content

Maintenance chemotherapy for ovarian cancer

  1. Ling Mei1,
  2. Hui Chen1,
  3. Dong Mei Wei1,
  4. Fang Fang1,*,
  5. Guan J Liu2,
  6. Huan Yu Xie3,
  7. Xun Wang1,
  8. Juan Zou1,
  9. Xu Han1,
  10. Dan Feng4

Editorial Group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group

Published Online: 29 JUN 2013

Assessed as up-to-date: 21 NOV 2012

DOI: 10.1002/14651858.CD007414.pub3


How to Cite

Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, Wang X, Zou J, Han X, Feng D. Maintenance chemotherapy for ovarian cancer. Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD007414. DOI: 10.1002/14651858.CD007414.pub3.

Author Information

  1. 1

    West China Second University Hospital, West China Women's and Children's Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China

  2. 2

    West China Hospital, Sichuan University, Chinese Cochrane Centre, Chinese Evidence-Based Medicine Centre, Chengdu, Sichuan, China

  3. 3

    People's Hospital of Deyang City, Department of Obstetrics and Gynecology, Deyang, Sichuan, China

  4. 4

    Cheng du Women & Children’s Central Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China

*Fang Fang, Department of Obstetrics and Gynecology, West China Second University Hospital, West China Women's and Children's Hospital, No. 17, Section Three, Ren Min Nan Lu Avenue, Chengdu, Sichuan, 610041, China. ffmn59@163.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 29 JUN 2013

SEARCH

[Figure 1]
Figure 1. Studies Selection
[Figure 2]
Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Maintenance chemotherapy versus observation, Outcome 1 3-year PFS.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Maintenance chemotherapy versus observation, Outcome 2 5-year PFS.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Maintenance chemotherapy versus observation, Outcome 3 10-year PFS.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Maintenance chemotherapy versus observation, Outcome 4 3-year OS.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Maintenance chemotherapy versus observation, Outcome 5 5-year OS.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Maintenance chemotherapy versus observation, Outcome 6 10-year OS.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Platin-based maintenance chemotherapy versus observation, Outcome 1 3-year PFS.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Platin-based maintenance chemotherapy versus observation, Outcome 2 5-year PFS.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Platin-based maintenance chemotherapy versus observation, Outcome 3 10-year PFS.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Platin-based maintenance chemotherapy versus observation, Outcome 4 3-year OS.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Platin-based maintenance chemotherapy versus observation, Outcome 5 5-year OS.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Platin-based maintenance chemotherapy versus observation, Outcome 6 10-year OS.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Doxorubicin-based maintenance chemotherapy versus observation, Outcome 1 3-year OS.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Doxorubicin-based maintenance chemotherapy versus observation, Outcome 2 5-year OS.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Maintenance chemotherapy versus maintenance radiotherapy, Outcome 1 3-year PFS.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Maintenance chemotherapy versus maintenance radiotherapy, Outcome 2 5-year PFS.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Maintenance chemotherapy versus maintenance radiotherapy, Outcome 3 10-year PFS.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Maintenance chemotherapy versus maintenance radiotherapy, Outcome 4 3-year OS.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Maintenance chemotherapy versus maintenance radiotherapy, Outcome 5 5-year OS.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Maintenance chemotherapy versus maintenance radiotherapy, Outcome 6 10-year OS.